2022 annual financial data
BioMarin Pharmaceutical 2022 Revenue growth
Direct answer
Revenue growth was 13.53%.
Operating income was 160,974,000 USD and net income was 141,561,000 USD.
Operating cash flow was 175,902,000 USD.
Get free BioMarin Pharmaceutical email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 2,096,039,000 USD
- Operating income
- 160,974,000 USD
- Net income
- 141,561,000 USD
- Operating cash flow
- 175,902,000 USD